JP7288431B2 - グルココルチコイドのインビボ投与によって介在される薬力学的応答をモニタリングするための方法 - Google Patents

グルココルチコイドのインビボ投与によって介在される薬力学的応答をモニタリングするための方法 Download PDF

Info

Publication number
JP7288431B2
JP7288431B2 JP2020512530A JP2020512530A JP7288431B2 JP 7288431 B2 JP7288431 B2 JP 7288431B2 JP 2020512530 A JP2020512530 A JP 2020512530A JP 2020512530 A JP2020512530 A JP 2020512530A JP 7288431 B2 JP7288431 B2 JP 7288431B2
Authority
JP
Japan
Prior art keywords
glucocorticoid
human
gene signature
glucocorticoids
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532302A5 (enExample
JP2020532302A (ja
Inventor
ジュリー・カーマン
ホゥ・ヤンホア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020532302A publication Critical patent/JP2020532302A/ja
Publication of JP2020532302A5 publication Critical patent/JP2020532302A5/ja
Application granted granted Critical
Publication of JP7288431B2 publication Critical patent/JP7288431B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
JP2020512530A 2017-08-30 2018-08-28 グルココルチコイドのインビボ投与によって介在される薬力学的応答をモニタリングするための方法 Active JP7288431B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551839P 2017-08-30 2017-08-30
US62/551,839 2017-08-30
PCT/US2018/048240 WO2019046233A1 (en) 2017-08-30 2018-08-28 METHOD FOR MONITORING PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO DELIVERY OF GLUCOCORTICOIDS

Publications (3)

Publication Number Publication Date
JP2020532302A JP2020532302A (ja) 2020-11-12
JP2020532302A5 JP2020532302A5 (enExample) 2021-08-19
JP7288431B2 true JP7288431B2 (ja) 2023-06-07

Family

ID=63678673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512530A Active JP7288431B2 (ja) 2017-08-30 2018-08-28 グルココルチコイドのインビボ投与によって介在される薬力学的応答をモニタリングするための方法

Country Status (7)

Country Link
US (1) US11421278B2 (enExample)
EP (1) EP3676402B1 (enExample)
JP (1) JP7288431B2 (enExample)
KR (1) KR102736851B1 (enExample)
CN (1) CN111051534B (enExample)
ES (1) ES2971091T3 (enExample)
WO (1) WO2019046233A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113990486B (zh) * 2021-10-27 2025-08-22 北京博富瑞医学检验实验室有限公司 一种基于aGVHD biomarker的一线糖皮质激素治疗反应预测模型

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503790A (ja) 2001-08-17 2005-02-10 インサイト・ゲノミックス・インコーポレイテッド 輸送体及びイオンチャネル
JP2014504272A (ja) 2010-11-10 2014-02-20 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
CN1193761C (zh) * 2003-06-25 2005-03-23 暨南大学 一种糖皮质激素的可控释放体系及其制备方法
SE0401032D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new acute glucocorticoid therapy
AU2005281352B2 (en) * 2004-09-09 2011-01-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
WO2013082288A1 (en) * 2011-11-29 2013-06-06 The Regents Of The University Of California Glucorticoid receptor gene nr3c1 methylation in irritable bowel syndrome and other stress disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503790A (ja) 2001-08-17 2005-02-10 インサイト・ゲノミックス・インコーポレイテッド 輸送体及びイオンチャネル
JP2014504272A (ja) 2010-11-10 2014-02-20 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neuropsychopharmacology，2012年，vol.37，p.1455-1464

Also Published As

Publication number Publication date
WO2019046233A1 (en) 2019-03-07
US11421278B2 (en) 2022-08-23
US20200299770A1 (en) 2020-09-24
CN111051534A (zh) 2020-04-21
ES2971091T3 (es) 2024-06-03
JP2020532302A (ja) 2020-11-12
EP3676402A1 (en) 2020-07-08
KR20200040872A (ko) 2020-04-20
EP3676402B1 (en) 2023-12-27
KR102736851B1 (ko) 2024-11-29
CN111051534B (zh) 2025-05-30

Similar Documents

Publication Publication Date Title
Paugh et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells
Bosco et al. Hypoxia modifies the transcriptome of primary human monocytes: modulation of novel immune-related genes and identification of CC-chemokine ligand 20 as a new hypoxia-inducible gene
Surjit et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor
Yu et al. T cell–intrinsic function of the noncanonical NF-κB pathway in the regulation of GM-CSF expression and experimental autoimmune encephalomyelitis pathogenesis
Seifuddin et al. Genome-wide Methyl-Seq analysis of blood-brain targets of glucocorticoid exposure
Lucafo et al. Long noncoding RNA GAS5: a novel marker involved in glucocorticoid response
US8647822B2 (en) Determining whether a test compound modulates PD-1 activity in activated immune cells using gene expression profiles
Hu et al. Development of a molecular signature to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids
Walters et al. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis
Suryani et al. Major depressive disorder patients on antidepressant treatments display higher number of regulatory T cells
Díaz et al. The clinical recovery of tuberculosis patients undergoing specific treatment is associated with changes in the immune and neuroendocrine responses
EP3781588B1 (en) Blood biomarker for eosinophilic gastrointestinal disorders
Greenough et al. A gene expression signature that correlates with CD8+ T cell expansion in acute EBV infection
Pilling et al. Gene expression markers of age-related inflammation in two human cohorts
Almon et al. Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens
CN109996895A (zh) 体外诊断精神障碍的方法和生物标志物
Søndergaard et al. Pregnancy-induced changes in microRNA expression in multiple sclerosis
Ambrose et al. The exaggerated inflammatory response in Behçet's syndrome: identification of dysfunctional post-transcriptional regulation of the IFN-γ/CXCL10 IP-10 pathway
Prado et al. Glucocorticoids enhance Th17/Th1 imbalance and signal transducer and activator of transcription 3 expression in systemic lupus erythematosus patients
JP7288431B2 (ja) グルココルチコイドのインビボ投与によって介在される薬力学的応答をモニタリングするための方法
Wang et al. Single-cell analysis with childhood and adult systemic lupus erythematosus
Fritsch-Stork et al. Expression of ERAP2 and LST1 is increased before start of therapy in rheumatoid arthritis patients with good clinical response to glucocorticoids
Whirledge et al. Generating diversity in human glucocorticoid signaling through a racially diverse polymorphism in the beta isoform of the glucocorticoid receptor
Dahm et al. A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women
Rawat et al. Genomics links inflammation with neurocognitive impairment in children living with human immunodeficiency virus type-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230526

R150 Certificate of patent or registration of utility model

Ref document number: 7288431

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150